Loading
companiesCompany
Adaptimmune
Adaptimmune developed Tecelra, the first TCR-T for a solid tumour, and sold the US rights to US WorldMeds in 2025 amid financial distress.
Overview
Adaptimmune, based in Abingdon and Philadelphia, developed Tecelra, or afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, and sold its US rights to US WorldMeds in 2025 amid financial distress. Afami-cel targets MAGE-A4 and was proved in SPEARHEAD-1 in synovial sarcoma, letetresgene autoleucel targets NY-ESO-1, and uza-cel, its PRAME programme, was sold. OnCo links it to sarcomas, to the afami-cel drug record and to the SPEARHEAD-1 papers. Whether a scientifically successful cell therapy can survive commercially in a rare cancer is the question its history answers, and the answer here was no. Afamitresgene autoleucel has its own page.
Headquarters
Abingdon / Philadelphia, GB
Scorecard
All companies#247of 1244 companies, score 20
- approved products +6
- targets +4
- modalities +2
- regions +1
- 24-month regulatory events +4
- registry trials +3
1 approved, 0 in phase 3, 0 earlier, 2 targets, 2 registry studies. Formula on the scorecards page.
Type
Website
ApprovedTCR-T (MAGE-A4)
Afamitresgene autoleucel · Tecelra
Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.
Similar pages
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- PersonSandra P. D'Angelo
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- TreatmentLetetresgene autoleucel
Shares IGNYTE-ESO, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- TrialSpearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Shares Afamitresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- TargetMAGE-A4
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- CompanyUS WorldMeds
Shares Afamitresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- PersonJean-Yves Blay
Shares SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- TermHLA-A*02:01 restriction
Shares Afamitresgene autoleucel, Sarcomas (soft tissue, bone, GIST).